NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

[...but there's a surfacing reality that just maybe NWBO is not up to the task.]

Yeah you're right. The last two years have been a walk in the desert, with no water for miles. Let's try sum up all these things that points to, that NWBO is not up to the task:

1) Have build infrastructure for manufactoring and production in Sawston, which is now MHRA certified

2) Have secured more than 260 patents and they keep on rolling in

3) During one year AdventBio have ramped up hiring at Sawston to over +40 people and now have state of the art cryostorage, and british medias have reported about this:

https://www.precisionvaccinations.com/2022/02/18/brain-cancer-vaccine-candidate-production-launches-uk
https://www.businessweekly.co.uk/news/biomedtech/cancer-vaccine-production-starts-cambridge
https://www.stocktitan.net/news/NWBO/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-kibldqlinbg8.html
https://www.cambridgeindependent.co.uk/business/advent-bioservices-gains-mhra-certification-for-sawston-bus-9237342/

4) They have been running biosimilarity and automation tests with Flaskworks and certification seems imminent, while they have announced at ASCO, they are soon able to scale to 12000 patients a year which is around $2-3B in revenue each year, when fully potential fully reached. Scaling further should be easy with the Flaskworks apparatus

5) More and more cancer organisations are now after the ASCO presentations and knowing endpoints have been reached, openly rooting for DCvax-L (counting 7-8 currently) and more and more oncologists do the same.

6) No one knows at this point, if approval at RAs has already been seeked, while waiting at the journal, but it is very clear now, with Bosch having visited a british cancer symposium march 2nd. undercover, with Linda Liau visiting England May 9th and we know from Hugh at Braintumorresearch.org in England yesterday in a response to an inquiry wrote

"We communicate directly with Linda Powers at NWBio and most recently facilitated her contributing to a meeting with UK politicians part of an inquiry into the pathway to a cure for brain tumour patients."


7) The UCLA SPORE 1 project is the combo trial with DCVax-L and Keytruda and Linda Liau has presented astounding news from this trial, with efficacy measured up to 50% with poly-iclc and Keytruda. She has been presenting a lot the last 6 months.

Of course NWBO and management is up to the task.

They are working around hours to accomplice all this, while maneouvring around all obstacles put in their way. Like manipulation from Market Makers to keep SP down. Naked shorting like the 4 million failed to deliver shares around May 10th. and Adam Feuerstein lying publicly about DCVax-L not being DCVax-L and then be the center of a short attack May 10th. with a hitpiece of an article filled with lies that two other newsmedias retract after they found out it was disinformation.

And that is exacly what some "shareholders" are afraid of.

That NWBO is very much up to the task to not only stay in the game, but to win against all odds.



https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired